ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
ARCA Biopharma Inc

ARCA Biopharma Inc (ABIO)

1.75
0.00
( 0.00% )
Updated: 14:00:37

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.75
Bid
1.74
Ask
1.76
Volume
5,453
1.7316 Day's Range 1.76
1.56 52 Week Range 2.16
Market Cap
Previous Close
1.75
Open
1.76
Last Trade
5
@
1.75
Last Trade Time
14:18:51
Financial Volume
$ 9,565
VWAP
1.7541
Average Volume (3m)
26,804
Shares Outstanding
14,501,143
Dividend Yield
-
PE Ratio
-4.75
Earnings Per Share (EPS)
-0.37
Revenue
-
Net Profit
-5.34M

About ARCA Biopharma Inc

ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome ... ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Show more

Sector
In Vitro,in Vivo Diagnostics
Industry
In Vitro,in Vivo Diagnostics
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
ARCA Biopharma Inc is listed in the In Vitro,in Vivo Diagnostics sector of the NASDAQ with ticker ABIO. The last closing price for ARCA Biopharma was $1.75. Over the last year, ARCA Biopharma shares have traded in a share price range of $ 1.56 to $ 2.16.

ARCA Biopharma currently has 14,501,143 shares outstanding. The market capitalization of ARCA Biopharma is $25.38 million. ARCA Biopharma has a price to earnings ratio (PE ratio) of -4.75.

ABIO Latest News

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES...

Form 8-K - Current report

0000907654false00009076542024-02-022024-02-02   UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section...

Form 8-K - Current report

false000090765400009076542024-02-012024-02-01   UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section...

ARCA biopharma Announces 2023 Financial Results

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Feb. 01, 2024 (GLOBE...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

falseFY0000907654http://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.01-0.5681818181821.761.81.69275941.74847672CS
40.16.060606060611.651.81.58277761.70219189CS
120.116.707317073171.641.81.56268041.65872323CS
26-0.26-12.93532338312.012.061.56252111.75814091CS
52-0.29-14.21568627452.042.161.56243801.90025113CS
156-1.94-52.57452574533.693.91.561199832.73693719CS
2601.3749366.5422553990.3751220.293297378.141403CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 23.1151
(386.63%)
22.67M
XLOXilio Therapeutics Inc
$ 1.49
(133.18%)
29.43M
NXLNexalin Technologies Inc
$ 1.7397
(123.04%)
4.98M
CEROCERo Therapeutics Holdings Inc
$ 2.99
(83.44%)
18.67M
BDRXBiodexa Pharmaceuticals PLC
$ 1.46
(69.97%)
83.46M
BOLDBoundless Bio Inc
 14.75
(-75.40%)
542.34k
PMECPrimech Holdings Ltd
$ 1.3908
(-64.15%)
6.62M
GMDAGamida Cell Ltd
$ 0.0353
(-40.37%)
73.33M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.2185
(-33.16%)
16.55M
NKLANikola Corporation
$ 1.04
(14.40%)
138.53M
BDRXBiodexa Pharmaceuticals PLC
$ 1.46
(69.97%)
83.46M
GMDAGamida Cell Ltd
$ 0.0353
(-40.37%)
73.33M
MARAMarathon Digital Holdings Inc
$ 23.09
(4.62%)
70.56M
AKANAkanda Corporation
$ 0.1501
(-8.98%)
67.64M

ABIO Discussion

View Posts
Monksdream Monksdream 2 weeks ago
ABIO under $2
πŸ‘οΈ0
BurgerKing82 BurgerKing82 3 months ago
Still no one comments here ... interesting if they come out with positive news.....
πŸ‘οΈ0
BurgerKing82 BurgerKing82 7 months ago
I'm surprised this board is so quiet....It's in such a tight 12 month Range...less than 15 mill shares....A history of huge jumps.... looks very compelling...
πŸ‘οΈ0
INFINITI INFINITI 2 years ago
ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data

Source: GlobeNewswire Inc.

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today provided an update on the ASPEN-COVID-19 Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with severe COVID-19. The Company announced that the Data and Safety Monitoring Committee (DSMC) has completed a pre-specified interim analysis and, based on the DSMC’s review of approximately 75% of the projected final efficacy and safety data, recommended completion of the clinical trial with no modifications to the trial design. The rNAPc2 development program has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). The Company now anticipates completion of target enrollment of 160 patients by year end 2021 and reporting of topline data in the first quarter of 2022.
Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, β€œClearing the final interim analysis with no recommended changes in the Phase 2b clinical trial design is an important step in a clinical trial and in the development of rNAPc2 for prevention of COVID-19-associated coagulopathy. We are focused on finishing the clinical trial, which we estimate will complete enrollment by year end. We look forward to sharing the top-line trial results in the first quarter of next year and reviewing the findings with the FDA.”

About ASPEN-COVID-19
ASPEN-COVID-19 is a Phase 2b randomized, multi-center, international clinical trial evaluating two dose regimens of rNAPc2 versus heparin in approximately 160 hospitalized SARS-CoV-2 positive patients that also have an elevated D-dimer level. The primary endpoint of the trial is the change in D-dimer level from baseline to Day 8 relative to standard of care heparin. D-dimer is a biomarker commonly used for assessing coagulation activation, which is elevated in approximately 40% to 75% of hospitalized COVID-19 patients and is associated with adverse clinical outcomes. Heparin is an anti-coagulant commonly given to any patient hospitalized in the United States for COVID-19. Other objectives of Phase 2b are to assess safety, determine the optimal dose regimen of rNAPc2 for a potential Phase 3 clinical trial and evaluate multiple additional clinical endpoints as detailed in the ASPEN-COVID-19 listing on clinicaltrials.gov.

The U.S. Food and Drug Administration (FDA) has designated the investigation of rNAPc2 as a potential treatment for COVID-19 as a Fast Track development program. ARCA believes that rNAPc2 is the only anticoagulant class new chemical entity in development for COVID-19.

About rNAPc2 (AB201)
rNAPc2 is a small recombinant protein being developed as a potential treatment for COVID-19 and potentially other viral diseases. rNAPc2 is a potent, selective inhibitor of tissue factor (TF), which has been identified as playing a central role in the inflammatory response to viral infections and in the process of viral dissemination. Its unique mechanism of action gives rNAPc2 a combination of anti-coagulant, anti-inflammatory and potential anti-viral properties, and therefore may be effective in addressing the impact of viral infections from multiple pathways. rNAPc2 has previously undergone Phase 1 and Phase 2 testing in more than 700 patients, including in clinical studies for prevention of venous and arterial thrombosis, where it showed efficacy in inhibiting the TF pathway and was well tolerated at therapeutic doses. Recent research suggests that the disease syndrome caused by coronavirus may have much in common with other severe infections in which the infection process causes inappropriate activation of the coagulation system and other aspects of the immune response, resulting in serious complications. Recent mechanistic discoveries, as well as prior data from studies in non-human primates (NHPs) given lethal doses of Ebola or Marburg filoviruses demonstrating morbidity and mortality reductions, decreases in inflammatory biomarkers and reduction in viral load, indicate that rNAPc2 may have important antiviral and anti-inflammatory activity in addition to its anticoagulant effects. The Company believes that collectively these observations provide a strong rationale for investigating rNAPc2 as a treatment for COVID-19 and other virus associated diseases.

About ARCA biopharma
ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA is developing rNAPc2 as a potential treatment for diseases caused by RNA viruses, initially focusing on COVID-19. The U.S. FDA has granted Fast Track designation to the rNAPc2 development program, currently in Phase 2 clinical testing. ARCA is also developing GencaroTM (bucindolol hydrochloride), an investigational, pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement. For more information, please visit www.arcabio.com or follow the Company on LinkedIn.

Safe Harbor Statement
This press release contains "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding potential future development plans for rNAPc2, the expected features and characteristics of rNAPc2, the anticipated development timeline for rNAPc2, rNAPc2’s potential to treat COVID-19, or any other RNA virus associated disease, whether rNAPc2 is the only anticoagulant class new chemical entity in development for COVID-19 and the potential future treatment options and needs for patients with COVID-19. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: ARCA’s financial resources and whether they will be sufficient to meet its business objectives and operational requirements; ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of rNAPc2 or to otherwise continue operations in the future; results of earlier clinical trials may not be confirmed in future trials; the protection and market exclusivity provided by ARCA’s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA’s filings with the Securities and Exchange Commission, including without limitation ARCA’s annual report on Form 10-K for the year ended December 31, 2020, and subsequent filings. ARCA disclaims any intent or obligation to update these forward-looking statements.

Investor & Media Contact:
Derek Cole
720.940.2163
derek.cole@arcabio.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg
πŸ‘οΈ0
INFINITI INFINITI 2 years ago
ARCA biopharma shares surge 30% on positive DSMC recommendation for rNAPc2 COVID-19 trial

Source: Seeking Alpha
To read the full story on Seeking Alpha, click here.
πŸ‘οΈ0
INFINITI INFINITI 2 years ago
Looks good got some $$$
πŸ‘οΈ0
newguy11 newguy11 3 years ago
Anyone know why we are up
πŸ‘οΈ0
llcoolm11 llcoolm11 3 years ago
ABIO Leaving the Train Station

All Aboard!!!
πŸ‘οΈ0
realfast95 realfast95 3 years ago
Chairman insider purchase

P 10000 A $4.163
πŸ‘οΈ0
tw0122 tw0122 3 years ago
Took a position on the $4.46 breakout can run some now
πŸ‘οΈ0
Femto99 Femto99 3 years ago
It should go back to PM high. They always do!
πŸ‘οΈ0
BottomBounce BottomBounce 3 years ago
Doubling down here $ABIO
πŸ‘οΈ0
BottomBounce BottomBounce 3 years ago
$ABIO ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
πŸ‘οΈ0
BottomBounce BottomBounce 3 years ago
BREAKOUT COMING
πŸ‘οΈ0
BottomBounce BottomBounce 3 years ago
ABIO MACD Bullish Crossover
πŸ‘οΈ0
BottomBounce BottomBounce 3 years ago
$ABIO ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.
Company Contact

Headquarters

11080 Circle Point Rd Ste 140
Westminster, CO 80020-2769

http://arcabio.com/
πŸ‘οΈ0
BottomBounce BottomBounce 3 years ago
$ABIO nice COVID19 pipeline
πŸ‘οΈ0
BottomBounce BottomBounce 3 years ago
Fauci: As many as 400,000 Americans could die from coronavirus
https://thehill.com/policy/healthcare/519935-fauci-as-many-as-400000-americans-could-die-from-coronavirus $ABIO
πŸ‘οΈ0
BottomBounce BottomBounce 3 years ago
$ABIO The 'evidence is clear': Hydroxychloroquine doesn't help Covid-19 patients
https://www.nbcnews.com/health/health-news/evidence-clear-hydroxychloroquine-doesn-t-help-covid-19-patients-n1242652
πŸ‘οΈ0
BottomBounce BottomBounce 3 years ago
loading zone $ABIO
πŸ‘οΈ0
BottomBounce BottomBounce 3 years ago
$ABIO New U.S. Coronavirus Cases Top 50,000 for the First Time in Five Days
https://www.wsj.com/articles/coronavirus-latest-news-10-08-2020-11602145213
πŸ‘οΈ0
BottomBounce BottomBounce 3 years ago
Fauci: As many as 400,000 Americans could die from coronavirus
https://thehill.com/policy/healthcare/519935-fauci-as-many-as-400000-americans-could-die-from-coronavirus
πŸ‘οΈ0
adtime adtime 3 years ago
Beauty trade 4.1-6.0 pm
πŸ‘οΈ0
BottomBounce BottomBounce 3 years ago
$ABIO FDA approval > ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19 https://www.globenewswire.com/news-release/2020/10/07/2104934/0/en/ARCA-biopharma-Announces-FDA-Approval-of-IND-Application-for-AB201-as-a-Potential-Treatment-for-COVID-19.html
πŸ‘οΈ0
MADDSTACKER MADDSTACKER 3 years ago
Grabbed a few
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
finshizzle shows 1.79M os.... no float info
sounds crazy tiny https://www.finviz.com/quote.ashx?t=abio
πŸ‘οΈ0
realfast95 realfast95 3 years ago

ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19
October 07 2020 - 08:30AM
GlobeNewswire Inc.


ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for AB201 (rNAPc2) as a potential treatment for patients hospitalized with COVID-19. ARCA anticipates initiating a Phase 2b/3 sequential clinical trial, ASPEN-COVID-19, of AB201 in approximately 100 patients hospitalized with COVID-19 in the fourth quarter of this year, with Phase 2b followed by a contiguous Phase 3 study that is dependent on Phase 2 results. The Company anticipates topline data from the trial in the second quarter of 2021.

The planned Phase 2b trial is anticipated to be a randomized comparison of two dose regimens of AB201 versus heparin prescribed per local standard of care. The clinical course of some patients with COVID-19 is complicated by a virus-triggered coagulopathy that includes thrombotic events and inflammatory processes, thought to be mediated in part by tissue factor production. AB201 is a potent tissue factor inhibitor anticoagulant with anti-inflammatory and antiviral properties. The primary endpoint of the trial will be change in D-dimer level from baseline to Day 8. D-dimer is a biomarker commonly used for assessing coagulation activation, which is elevated in approximately 50% of hospitalized COVID-19 patients and is directly associated with adverse clinical outcomes. If Phase 2b indicates a favorable effect on D-dimer levels, following FDA review of the data and identification of the proposed Phase 3 AB201 dose, the Company anticipates that clinical investigative sites will begin enrolling in the planned Phase 3 clinical trial. The primary endpoint of Phase 3 will be clinical recovery as measured by the Adaptive COVID-19 Treatment Trial (ACTT-1) ordinal scale, with secondary endpoints that include D-dimer levels and the number of thrombotic events. Phase 3 will be event driven, with an estimated requirement of 450 patients. The Phase 2b and Phase 3 trials are described in a common protocol and use identical entry criteria and the same heparin regimen control.

Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, who is also an American Heart Association (AHA) funded COVID-19 investigator, commented, "The ASPEN-COVID-19 trial will use the coagulopathy biomarker D-dimer to identify an optimal dose from AB201 regimens that are both within the therapeutic range as determined from Phase 2 trials investigating cardiovascular thrombosis prophylaxis. If successful, we anticipate using this dose in a planned Phase 3 trial to evaluate potential improvement in clinical outcomes. We believe that the combination of anticoagulant, anti-inflammatory and antiviral effects of AB201 may favorably impact clinical recovery of patients hospitalized with COVID-19."

The trial is being managed in collaboration with the Colorado Prevention Center (CPC), the University of Colorado's Academic Research Organization with extensive experience in managing vascular and anticoagulation clinical trials.

Marc Bonaca, MD, Executive Director of CPC, commented: β€œThe ASPEN-COVID-19 trial will enable us to step beyond the question of intensity of anticoagulation and ask the question of whether specifically targeting tissue factor, a key step in the extrinsic pathway of anticoagulation and a key part of viral pathogenesis, improves outcomes in COVID-19. Dosing and safety are critical, and the Phase 2 trial will enable selection of a dose for safety, coagulopathy, and anti-viral parameters for use in a planned Phase 3 clinical trial. This selected dose will be deployed in the proposed Phase 3 pivotal outcomes study with the hope of translation to the clinical setting. We believe this therapy holds promise to improve outcomes in the current pandemic and given the positive findings in an Ebola animal model, has the potential for broader application in other severe viral infections characterized by coagulopathy.”
πŸ‘οΈ0
adtime adtime 3 years ago
How we doing from alert?
πŸ‘οΈ0
realfast95 realfast95 3 years ago
trending on stocktwits
πŸ‘οΈ0
adtime adtime 4 years ago
Insiders buying. Fda approval next catalyst. Offering was much higher at 9. Low float. Funded until end of 2021.

Tick tock
πŸ‘οΈ0
mick mick 4 years ago
ARCA Biopharma Inc (ABIO)
4.57 ? 0.5 (12.29%)
Volume: 675,511 @09/25/20 7:25:52 PM EDT
Bid Ask Day's Range
4.47 4.59 4.16 - 4.5499
ABIO Detailed Quote
πŸ‘οΈ0
realfast95 realfast95 4 years ago
Chairman continues to buy shares
πŸ‘οΈ0
stock1ace1 stock1ace1 4 years ago
News -> ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201 as a Potential Treatment for Severe COVID-19
[8:01 AM]
πŸ‘οΈ0
stock1ace1 stock1ace1 4 years ago
Buying tiny float almost 1 mill vol in p/m !
πŸ‘οΈ0
alchemytrader alchemytrader 4 years ago
pop over 8.40 and back down 6.95
πŸ‘οΈ0
Crazy Money Crazy Money 4 years ago
$7
πŸ‘οΈ0
price_and_volume price_and_volume 4 years ago
Good calls on VVUSQ fwiw...

One of the few on that board who understood what was going on there

πŸ‘οΈ0
llcoolm11 llcoolm11 4 years ago
Opened a starter position today at $7.30.
The drop from $19.21 to today's closing price of $7.29 is excessive.
Reversal coming.
πŸ‘οΈ0
stock1ace1 stock1ace1 4 years ago
Great setup abio$7.88
πŸ‘οΈ0
Golden Cross Golden Cross 4 years ago
Looks good!
πŸ‘οΈ0
stock1ace1 stock1ace1 4 years ago
1 mill float !
πŸ‘οΈ0
Popcorncharts Popcorncharts 4 years ago
We have a new Drug for Investors AB2020 we dilut 100 Millions and starting this week with the Study ! The new Drug make you Brain great for lose Money
πŸ‘οΈ0
Popcorncharts Popcorncharts 4 years ago
WARNING FOR THIS SCAM! EBOLA SCAM COVID SCAM FOR DILUT
πŸ‘οΈ0
Popcorncharts Popcorncharts 4 years ago
Scam new dilut 50% Long Investor lose 99.9% BIG SCAM
πŸ‘οΈ0
Popcorncharts Popcorncharts 4 years ago
Long Investors lose all Money ! Management dilut 99.9 ! This is so a big scam
πŸ‘οΈ0
Popcorncharts Popcorncharts 4 years ago
INVESTING WARNING THIS SCAM HAVE NOT COVID-19 pipelines! THIS IS LYING AND FRAUD PUMP AND DUMP
πŸ‘οΈ0
Golden Cross Golden Cross 4 years ago
Bouncing here...hee haw
πŸ‘οΈ0
europtiger europtiger 4 years ago
Got 8,70,s
πŸ‘οΈ0
europtiger europtiger 4 years ago
Thx for heads up... buying some 8,80β€˜s
πŸ‘οΈ0
TheFinalCD TheFinalCD 4 years ago
https://ih.advfn.com/stock-market/NASDAQ/arca-biopharma-ABIO/stock-news/82636540/statement-of-ownership-sc-13g
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock